Gabapentin Market
Gabapentin Market Forecasts to 2030 - Global Analysis By Product (Tablet, Capsule and Other Products), Type (Generic, Branded and Other Types), Route of Administration, Mode of Purchase, Application, End User and By Geography
|
Years Covered |
2021-2030 |
|
Estimated Year Value (2023) |
US $2,171.52 MN |
|
Projected Year Value (2030) |
US $3,567.61 MN |
|
CAGR (2023 - 2030) |
7.4% |
|
Regions Covered |
North America, Europe, Asia Pacific, South America, and Middle East & Africa |
|
Countries Covered |
US, Canada, Mexico, Germany, UK, Italy, France, Spain, Japan, China, India, Australia, New Zealand, South Korea, Rest of Asia Pacific, South America, Argentina, Brazil, Chile, Middle East & Africa, Saudi Arabia, UAE, Qatar, and South Africa |
|
Largest Market |
North America |
|
Highest Growing Market |
Europe |
According to Stratistics MRC, the Global Gabapentin Market is accounted for $2,171.52 million in 2023 and is expected to reach $3,567.61 million by 2030 growing at a CAGR of 7.4% during the forecast period. Gabapentin is a pharmaceutical compound used primarily as an anticonvulsant and to alleviate neuropathic pain which mimic the neurotransmitter gamma-aminobutyric acid (GABA). It is approved by the U.S. Food and Drug Administration (FDA), and is employed in the treatment of various medical conditions, including epilepsy, postherpetic neuralgia, and restless legs syndrome. The drug's versatility in addressing neurological disorders and chronic pain has made it a valuable asset in modern medicine.
According to a report, gabapentin ranks sixth in prescribed medication in the United States in 2020. Nearly, 57 million prescriptions were written for the drug in the country in 2020.
Market Dynamics:
Driver:
Increase in awareness
Healthcare professionals and patients are becoming more informed about the drug's efficacy in managing various neurological disorders and neuropathic pain conditions. Physicians are increasingly prescribing Gabapentin based on a deeper understanding of its mechanisms of action and the diverse range of conditions it can effectively address. In addition, the evolving landscape of patient-centered healthcare encourages informed decision-making, making awareness a crucial factor in driving this market.
Restraint:
Misuse and abuse
Gabapentin misuse can involve taking higher doses than prescribed, using it without a prescription, or combining it with other substances to intensify the desired effects. Abuse of gabapentin can result in various adverse effects, including dizziness, sedation, impaired coordination, blurred vision, and cognitive difficulties. Furthermore, abrupt discontinuation of gabapentin after prolonged misuse or abuse can result in withdrawal symptoms such as anxiety, insomnia, and restlessness, significantly hampering this market expansion.
Opportunity:
Telehealth expansion
The expansion of telehealth services serves healthcare and positively impacts the accessibility of this medication by transforming easy delivery for individuals requiring gabapentin for neurological disorders and neuropathic pain. Telehealth allows healthcare providers to conduct remote consultations, prescribe medications, and monitor patients' conditions from a distance. Further, telehealth enables healthcare professionals to monitor patients remotely, address concerns promptly, and optimize medication management, which is propelling this market
Threat:
Side effects and tolerance
The prevalence of side effects poses challenges for healthcare providers in balancing the therapeutic benefits of Gabapentin with its potential drawbacks. Patient-specific factors, such as age, underlying health conditions, and concurrent medications, can influence the likelihood and severity of side effects. Moreover, the presence of side effects may necessitate additional medical interventions, contributing to healthcare costs and resource utilization and thereby hindering market growth.
Covid-19 Impact
The COVID-19 pandemic has had several negative impacts on the Gabapentin market. Supply chain disruptions, lockdown measures, and shifts in healthcare priorities have collectively contributed to challenges in the production, distribution, and consumption of gabapentin. Economic uncertainties and financial strains on healthcare systems have prompted cost-cutting measures, potentially influencing the affordability of Gabapentin. Moreover, reduced patient visits to healthcare providers may have led to a decline in new prescriptions and refills, affecting overall market demand.
The capsule segment is expected to be the largest during the forecast period
The capsule segment is estimated to hold the largest share. These are pharmaceutical products widely prescribed for neurological disorders and neuropathic pain that are efficient in managing conditions like epilepsy, postherpetic neuralgia, and diabetic neuropathy. Factors such as research and development initiatives, regulatory approvals, and strategic collaborations influence market dynamics. Furthermore, a focus on innovation, safety, and accessibility continues to be a vital contributor to the broader pharmaceutical market, driving this segment’s growth.
The parenteral segment is expected to have the highest CAGR during the forecast period
The parenteral segment is anticipated to have highest CAGR during the forecast period due to distinct advantages, particularly in situations where oral intake may be challenging, such as for patients experiencing nausea, vomiting, or those with difficulty swallowing. This mode of delivery enhances treatment compliance and ensures patients receive the prescribed dosage accurately. Additionally, for individuals requiring rapid onset of action or precise dosage control, parenteral formulations of gabapentin provide an effective alternative, boosting this segment’s expansion.
Region with largest share:
North America commanded the largest market share during the extrapolated period owing to its significant presence in the pharmaceutical landscape, addressing neurological disorders and neuropathic pain. Key markets such as Pfizer Inc., Teva Pharmaceuticals Ltd., Glenmark Pharmaceuticals Limited, and Cipla USA Inc. have become cornerstones in the management of conditions like epilepsy, postherpetic neuralgia, and diabetic neuropathy. Furthermore, regulatory oversight from agencies like the U.S. Food and Drug Administration (FDA) and Health Canada ensures compliance with safety standards and effective distribution in this region.
Region with highest CAGR:
Europe is expected to witness highest CAGR over the projection period, owing to its efficacy in managing conditions like epilepsy, postherpetic neuralgia, and diabetic neuropathy. Pharmaceutical companies engage in manufacturing and marketing activities to meet the increasing demand for Gabapentin, aiming to provide effective solutions for individuals grappling with neurological conditions in Europe. In addition, factors such as the rising prevalence of neurological disorders, an aging population, and an increased awareness of chronic pain management are boosting this region’s expansion.
Key players in the market
Some of the key players in the Gabapentin Market include Amneal Pharmaceuticals LLC., Intas Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd, Marksans Pharma, Novartis AG, Alkem Labs, Jiangsu Nhwa Pharmaceutical Co., Ltd, Aurobindo Pharma, Apotex Inc, Viatris Inc, Arbor Pharmaceuticals, LLC, Pfizer Inc, Teva Pharmaceuticals Ltd, Glenmark Pharmaceuticals Limited, Ascend Laboratories, LLC and Cipla USA, Inc.
Key Developments:
In December 2023, Pfizer Inc. announced the successful completion of its acquisition of Seagen Inc, a global biotechnology company that discovers, develops and commercializes transformative cancer medicines.
In October 2023, Zydus Lifesciences Company and Sun Pharmaceutical Industries Limited announced that both companies have entered into a licensing agreement to co-market an innovative drug, Desidustat in India.
In January 2023, Sun Pharmaceutical Industries Limited and Concert Pharmaceuticals, Inc. announced that they have executed a definitive agreement under which Sun Pharma will acquire all outstanding shares of Concert through a tender offer for an upfront payment in equity value.
Products Covered:
• Tablet
• Capsule
• Other Products
Types Covered:
• Generic
• Branded
• Other Types
Route of Administrations Covered:
• Parenteral
• Oral
• Intravenous
• Other Route of Administrations
Mode of Purchase Covered:
• Prescription
• Over the Counter(OTC)
• Retail
Applications Covered:
• Neuropathic Pain
• Epilepsy
• Restless Legs Syndrome
• Other Applications
End Users Covered:
• Online Pharmacies
• Hospital Pharmacy
• Other End Users
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 Application Analysis
3.8 End User Analysis
3.9 Emerging Markets
3.10 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Gabapentin Market, By Product
5.1 Introduction
5.2 Tablet
5.3 Capsule
5.4 Other Products
6 Global Gabapentin Market, By Type
6.1 Introduction
6.2 Generic
6.3 Branded
6.4 Other Types
7 Global Gabapentin Market, By Route of Administration
7.1 Introduction
7.2 Parenteral
7.3 Oral
7.4 Intravenous
7.5 Other Route of Administrations
8 Global Gabapentin Market, By Mode of Purchase
8.1 Introduction
8.2 Prescription
8.3 Over the Counter (OTC)
8.4 Retail
9 Global Gabapentin Market, By Application
9.1 Introduction
9.2 Neuropathic Pain
9.3 Epilepsy
9.4 Restless Legs Syndrome
9.5 Other Applications
10 Global Gabapentin Market, By End User
10.1 Introduction
10.2 Online Pharmacies
10.3 Hospital Pharmacy
10.4 Other End Users
11 Global Gabapentin Market, By Geography
11.1 Introduction
11.2 North America
11.2.1 US
11.2.2 Canada
11.2.3 Mexico
11.3 Europe
11.3.1 Germany
11.3.2 UK
11.3.3 Italy
11.3.4 France
11.3.5 Spain
11.3.6 Rest of Europe
11.4 Asia Pacific
11.4.1 Japan
11.4.2 China
11.4.3 India
11.4.4 Australia
11.4.5 New Zealand
11.4.6 South Korea
11.4.7 Rest of Asia Pacific
11.5 South America
11.5.1 Argentina
11.5.2 Brazil
11.5.3 Chile
11.5.4 Rest of South America
11.6 Middle East & Africa
11.6.1 Saudi Arabia
11.6.2 UAE
11.6.3 Qatar
11.6.4 South Africa
11.6.5 Rest of Middle East & Africa
12 Key Developments
12.1 Agreements, Partnerships, Collaborations and Joint Ventures
12.2 Acquisitions & Mergers
12.3 New Product Launch
12.4 Expansions
12.5 Other Key Strategies
13 Company Profiling
13.1 Amneal Pharmaceuticals LLC.
13.2 Intas Pharmaceuticals Ltd.
13.3 Sun Pharmaceutical Industries Ltd
13.4 Marksans Pharma
13.5 Novartis AG
13.6 Alkem Labs
13.7 Jiangsu Nhwa Pharmaceutical Co., Ltd
13.8 Aurobindo Pharma
13.9 Apotex Inc
13.10 Viatris Inc
13.11 Arbor Pharmaceuticals, LLC
13.12 Pfizer Inc
13.13 Teva Pharmaceuticals Ltd
13.14 Glenmark Pharmaceuticals Limited
13.15 Ascend Laboratories, LLC
13.16 Cipla USA, Inc.
List of Tables
1 Global Gabapentin Market Outlook, By Region (2021-2030) ($MN)
2 Global Gabapentin Market Outlook, By Product (2021-2030) ($MN)
3 Global Gabapentin Market Outlook, By Tablet (2021-2030) ($MN)
4 Global Gabapentin Market Outlook, By Capsule (2021-2030) ($MN)
5 Global Gabapentin Market Outlook, By Other Products (2021-2030) ($MN)
6 Global Gabapentin Market Outlook, By Type (2021-2030) ($MN)
7 Global Gabapentin Market Outlook, By Generic (2021-2030) ($MN)
8 Global Gabapentin Market Outlook, By Branded (2021-2030) ($MN)
9 Global Gabapentin Market Outlook, By Other Types (2021-2030) ($MN)
10 Global Gabapentin Market Outlook, By Route of Administration (2021-2030) ($MN)
11 Global Gabapentin Market Outlook, By Parenteral (2021-2030) ($MN)
12 Global Gabapentin Market Outlook, By Oral (2021-2030) ($MN)
13 Global Gabapentin Market Outlook, By Intravenous (2021-2030) ($MN)
14 Global Gabapentin Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
15 Global Gabapentin Market Outlook, By Mode of Purchase (2021-2030) ($MN)
16 Global Gabapentin Market Outlook, By Prescription (2021-2030) ($MN)
17 Global Gabapentin Market Outlook, By Over the Counter (OTC) (2021-2030) ($MN)
18 Global Gabapentin Market Outlook, By Retail (2021-2030) ($MN)
19 Global Gabapentin Market Outlook, By Application (2021-2030) ($MN)
20 Global Gabapentin Market Outlook, By Neuropathic Pain (2021-2030) ($MN)
21 Global Gabapentin Market Outlook, By Epilepsy (2021-2030) ($MN)
22 Global Gabapentin Market Outlook, By Restless Legs Syndrome (2021-2030) ($MN)
23 Global Gabapentin Market Outlook, By Other Applications (2021-2030) ($MN)
24 Global Gabapentin Market Outlook, By End User (2021-2030) ($MN)
25 Global Gabapentin Market Outlook, By Online Pharmacies (2021-2030) ($MN)
26 Global Gabapentin Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
27 Global Gabapentin Market Outlook, By Other End Users (2021-2030) ($MN)
28 North America Gabapentin Market Outlook, By Country (2021-2030) ($MN)
29 North America Gabapentin Market Outlook, By Product (2021-2030) ($MN)
30 North America Gabapentin Market Outlook, By Tablet (2021-2030) ($MN)
31 North America Gabapentin Market Outlook, By Capsule (2021-2030) ($MN)
32 North America Gabapentin Market Outlook, By Other Products (2021-2030) ($MN)
33 North America Gabapentin Market Outlook, By Type (2021-2030) ($MN)
34 North America Gabapentin Market Outlook, By Generic (2021-2030) ($MN)
35 North America Gabapentin Market Outlook, By Branded (2021-2030) ($MN)
36 North America Gabapentin Market Outlook, By Other Types (2021-2030) ($MN)
37 North America Gabapentin Market Outlook, By Route of Administration (2021-2030) ($MN)
38 North America Gabapentin Market Outlook, By Parenteral (2021-2030) ($MN)
39 North America Gabapentin Market Outlook, By Oral (2021-2030) ($MN)
40 North America Gabapentin Market Outlook, By Intravenous (2021-2030) ($MN)
41 North America Gabapentin Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
42 North America Gabapentin Market Outlook, By Mode of Purchase (2021-2030) ($MN)
43 North America Gabapentin Market Outlook, By Prescription (2021-2030) ($MN)
44 North America Gabapentin Market Outlook, By Over the Counter (OTC) (2021-2030) ($MN)
45 North America Gabapentin Market Outlook, By Retail (2021-2030) ($MN)
46 North America Gabapentin Market Outlook, By Application (2021-2030) ($MN)
47 North America Gabapentin Market Outlook, By Neuropathic Pain (2021-2030) ($MN)
48 North America Gabapentin Market Outlook, By Epilepsy (2021-2030) ($MN)
49 North America Gabapentin Market Outlook, By Restless Legs Syndrome (2021-2030) ($MN)
50 North America Gabapentin Market Outlook, By Other Applications (2021-2030) ($MN)
51 North America Gabapentin Market Outlook, By End User (2021-2030) ($MN)
52 North America Gabapentin Market Outlook, By Online Pharmacies (2021-2030) ($MN)
53 North America Gabapentin Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
54 North America Gabapentin Market Outlook, By Other End Users (2021-2030) ($MN)
55 Europe Gabapentin Market Outlook, By Country (2021-2030) ($MN)
56 Europe Gabapentin Market Outlook, By Product (2021-2030) ($MN)
57 Europe Gabapentin Market Outlook, By Tablet (2021-2030) ($MN)
58 Europe Gabapentin Market Outlook, By Capsule (2021-2030) ($MN)
59 Europe Gabapentin Market Outlook, By Other Products (2021-2030) ($MN)
60 Europe Gabapentin Market Outlook, By Type (2021-2030) ($MN)
61 Europe Gabapentin Market Outlook, By Generic (2021-2030) ($MN)
62 Europe Gabapentin Market Outlook, By Branded (2021-2030) ($MN)
63 Europe Gabapentin Market Outlook, By Other Types (2021-2030) ($MN)
64 Europe Gabapentin Market Outlook, By Route of Administration (2021-2030) ($MN)
65 Europe Gabapentin Market Outlook, By Parenteral (2021-2030) ($MN)
66 Europe Gabapentin Market Outlook, By Oral (2021-2030) ($MN)
67 Europe Gabapentin Market Outlook, By Intravenous (2021-2030) ($MN)
68 Europe Gabapentin Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
69 Europe Gabapentin Market Outlook, By Mode of Purchase (2021-2030) ($MN)
70 Europe Gabapentin Market Outlook, By Prescription (2021-2030) ($MN)
71 Europe Gabapentin Market Outlook, By Over the Counter (OTC) (2021-2030) ($MN)
72 Europe Gabapentin Market Outlook, By Retail (2021-2030) ($MN)
73 Europe Gabapentin Market Outlook, By Application (2021-2030) ($MN)
74 Europe Gabapentin Market Outlook, By Neuropathic Pain (2021-2030) ($MN)
75 Europe Gabapentin Market Outlook, By Epilepsy (2021-2030) ($MN)
76 Europe Gabapentin Market Outlook, By Restless Legs Syndrome (2021-2030) ($MN)
77 Europe Gabapentin Market Outlook, By Other Applications (2021-2030) ($MN)
78 Europe Gabapentin Market Outlook, By End User (2021-2030) ($MN)
79 Europe Gabapentin Market Outlook, By Online Pharmacies (2021-2030) ($MN)
80 Europe Gabapentin Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
81 Europe Gabapentin Market Outlook, By Other End Users (2021-2030) ($MN)
82 Asia Pacific Gabapentin Market Outlook, By Country (2021-2030) ($MN)
83 Asia Pacific Gabapentin Market Outlook, By Product (2021-2030) ($MN)
84 Asia Pacific Gabapentin Market Outlook, By Tablet (2021-2030) ($MN)
85 Asia Pacific Gabapentin Market Outlook, By Capsule (2021-2030) ($MN)
86 Asia Pacific Gabapentin Market Outlook, By Other Products (2021-2030) ($MN)
87 Asia Pacific Gabapentin Market Outlook, By Type (2021-2030) ($MN)
88 Asia Pacific Gabapentin Market Outlook, By Generic (2021-2030) ($MN)
89 Asia Pacific Gabapentin Market Outlook, By Branded (2021-2030) ($MN)
90 Asia Pacific Gabapentin Market Outlook, By Other Types (2021-2030) ($MN)
91 Asia Pacific Gabapentin Market Outlook, By Route of Administration (2021-2030) ($MN)
92 Asia Pacific Gabapentin Market Outlook, By Parenteral (2021-2030) ($MN)
93 Asia Pacific Gabapentin Market Outlook, By Oral (2021-2030) ($MN)
94 Asia Pacific Gabapentin Market Outlook, By Intravenous (2021-2030) ($MN)
95 Asia Pacific Gabapentin Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
96 Asia Pacific Gabapentin Market Outlook, By Mode of Purchase (2021-2030) ($MN)
97 Asia Pacific Gabapentin Market Outlook, By Prescription (2021-2030) ($MN)
98 Asia Pacific Gabapentin Market Outlook, By Over the Counter (OTC) (2021-2030) ($MN)
99 Asia Pacific Gabapentin Market Outlook, By Retail (2021-2030) ($MN)
100 Asia Pacific Gabapentin Market Outlook, By Application (2021-2030) ($MN)
101 Asia Pacific Gabapentin Market Outlook, By Neuropathic Pain (2021-2030) ($MN)
102 Asia Pacific Gabapentin Market Outlook, By Epilepsy (2021-2030) ($MN)
103 Asia Pacific Gabapentin Market Outlook, By Restless Legs Syndrome (2021-2030) ($MN)
104 Asia Pacific Gabapentin Market Outlook, By Other Applications (2021-2030) ($MN)
105 Asia Pacific Gabapentin Market Outlook, By End User (2021-2030) ($MN)
106 Asia Pacific Gabapentin Market Outlook, By Online Pharmacies (2021-2030) ($MN)
107 Asia Pacific Gabapentin Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
108 Asia Pacific Gabapentin Market Outlook, By Other End Users (2021-2030) ($MN)
109 South America Gabapentin Market Outlook, By Country (2021-2030) ($MN)
110 South America Gabapentin Market Outlook, By Product (2021-2030) ($MN)
111 South America Gabapentin Market Outlook, By Tablet (2021-2030) ($MN)
112 South America Gabapentin Market Outlook, By Capsule (2021-2030) ($MN)
113 South America Gabapentin Market Outlook, By Other Products (2021-2030) ($MN)
114 South America Gabapentin Market Outlook, By Type (2021-2030) ($MN)
115 South America Gabapentin Market Outlook, By Generic (2021-2030) ($MN)
116 South America Gabapentin Market Outlook, By Branded (2021-2030) ($MN)
117 South America Gabapentin Market Outlook, By Other Types (2021-2030) ($MN)
118 South America Gabapentin Market Outlook, By Route of Administration (2021-2030) ($MN)
119 South America Gabapentin Market Outlook, By Parenteral (2021-2030) ($MN)
120 South America Gabapentin Market Outlook, By Oral (2021-2030) ($MN)
121 South America Gabapentin Market Outlook, By Intravenous (2021-2030) ($MN)
122 South America Gabapentin Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
123 South America Gabapentin Market Outlook, By Mode of Purchase (2021-2030) ($MN)
124 South America Gabapentin Market Outlook, By Prescription (2021-2030) ($MN)
125 South America Gabapentin Market Outlook, By Over the Counter (OTC) (2021-2030) ($MN)
126 South America Gabapentin Market Outlook, By Retail (2021-2030) ($MN)
127 South America Gabapentin Market Outlook, By Application (2021-2030) ($MN)
128 South America Gabapentin Market Outlook, By Neuropathic Pain (2021-2030) ($MN)
129 South America Gabapentin Market Outlook, By Epilepsy (2021-2030) ($MN)
130 South America Gabapentin Market Outlook, By Restless Legs Syndrome (2021-2030) ($MN)
131 South America Gabapentin Market Outlook, By Other Applications (2021-2030) ($MN)
132 South America Gabapentin Market Outlook, By End User (2021-2030) ($MN)
133 South America Gabapentin Market Outlook, By Online Pharmacies (2021-2030) ($MN)
134 South America Gabapentin Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
135 South America Gabapentin Market Outlook, By Other End Users (2021-2030) ($MN)
136 Middle East & Africa Gabapentin Market Outlook, By Country (2021-2030) ($MN)
137 Middle East & Africa Gabapentin Market Outlook, By Product (2021-2030) ($MN)
138 Middle East & Africa Gabapentin Market Outlook, By Tablet (2021-2030) ($MN)
139 Middle East & Africa Gabapentin Market Outlook, By Capsule (2021-2030) ($MN)
140 Middle East & Africa Gabapentin Market Outlook, By Other Products (2021-2030) ($MN)
141 Middle East & Africa Gabapentin Market Outlook, By Type (2021-2030) ($MN)
142 Middle East & Africa Gabapentin Market Outlook, By Generic (2021-2030) ($MN)
143 Middle East & Africa Gabapentin Market Outlook, By Branded (2021-2030) ($MN)
144 Middle East & Africa Gabapentin Market Outlook, By Other Types (2021-2030) ($MN)
145 Middle East & Africa Gabapentin Market Outlook, By Route of Administration (2021-2030) ($MN)
146 Middle East & Africa Gabapentin Market Outlook, By Parenteral (2021-2030) ($MN)
147 Middle East & Africa Gabapentin Market Outlook, By Oral (2021-2030) ($MN)
148 Middle East & Africa Gabapentin Market Outlook, By Intravenous (2021-2030) ($MN)
149 Middle East & Africa Gabapentin Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
150 Middle East & Africa Gabapentin Market Outlook, By Mode of Purchase (2021-2030) ($MN)
151 Middle East & Africa Gabapentin Market Outlook, By Prescription (2021-2030) ($MN)
152 Middle East & Africa Gabapentin Market Outlook, By Over the Counter (OTC) (2021-2030) ($MN)
153 Middle East & Africa Gabapentin Market Outlook, By Retail (2021-2030) ($MN)
154 Middle East & Africa Gabapentin Market Outlook, By Application (2021-2030) ($MN)
155 Middle East & Africa Gabapentin Market Outlook, By Neuropathic Pain (2021-2030) ($MN)
156 Middle East & Africa Gabapentin Market Outlook, By Epilepsy (2021-2030) ($MN)
157 Middle East & Africa Gabapentin Market Outlook, By Restless Legs Syndrome (2021-2030) ($MN)
158 Middle East & Africa Gabapentin Market Outlook, By Other Applications (2021-2030) ($MN)
159 Middle East & Africa Gabapentin Market Outlook, By End User (2021-2030) ($MN)
160 Middle East & Africa Gabapentin Market Outlook, By Online Pharmacies (2021-2030) ($MN)
161 Middle East & Africa Gabapentin Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
162 Middle East & Africa Gabapentin Market Outlook, By Other End Users (2021-2030) ($MN)
List of Figures
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.
